{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:31:28Z","timestamp":1791070288834,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/mao.0b013e31825e73f5","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T07:56:13Z","timestamp":1342252573000},"page":"1046-1052","source":"Crossref","is-referenced-by-count":243,"title":["Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2"],"prefix":"10.1097","volume":"33","author":[{"given":"Scott R.","family":"Plotkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20210212","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jmg.37.12.897","article-title":"Neurofibromatosis type 2.","volume":"37","author":"Evans","year":"2000","journal-title":"J Med Genet"},{"key":"R2-25-20210212","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00129492-200409000-00027","article-title":"Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.","volume":"25","author":"Slattery","year":"2004","journal-title":"Otol Neurotol"},{"key":"R3-25-20210212","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00129492-200403000-00012","article-title":"Hearing changes after diagnosis in neurofibromatosis type 2.","volume":"25","author":"Masuda","year":"2004","journal-title":"Otol Neurotol"},{"key":"R4-25-20210212","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"key":"R5-25-20210212","doi-asserted-by":"crossref","first-page":"188","DOI":"10.7326\/0003-4819-113-3-188","article-title":"Quality-of-life changes and hearing impairment. A randomized trial.","volume":"113","author":"Mulrow","year":"1990","journal-title":"Ann Intern Med"},{"key":"R6-25-20210212","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1080\/14992020802310887","article-title":"Hearing impairment, work, and vocational enablement.","volume":"2","author":"Kramer","year":"2008","journal-title":"Int J Audiol Suppl"},{"key":"R7-25-20210212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/AUD.0b013e31803126b6","article-title":"Hearin impairment and health-related quality of life: the Blue Mountains Hearing Study.","volume":"28","author":"Chia","year":"2007","journal-title":"Ear Hear"},{"key":"R8-25-20210212","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-25-20210212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"key":"R10-25-20210212","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","article-title":"Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.","volume":"126","author":"Eminowicz","year":"2012","journal-title":"J Laryngol Otol"},{"key":"R11-25-20210212","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","article-title":"Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.","volume":"21","author":"Mautner","year":"2010","journal-title":"Ann Oncol"},{"key":"R12-25-20210212","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","article-title":"NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.","volume":"113","author":"Mulvihill","year":"1990","journal-title":"Ann Intern Med"},{"key":"R13-25-20210212","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","article-title":"Evaluation of clinical diagnostic criteria for neurofibromatosis 2.","volume":"59","author":"Baser","year":"2002","journal-title":"Neurology"},{"key":"R14-25-20210212","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1227\/01.neu.0000333303.79931.83","article-title":"Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.","volume":"62","author":"Harris","year":"2008","journal-title":"Neurosurgery"},{"key":"R15-25-20210212","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"R16-25-20210212","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0194-5998(95)70100-1","article-title":"New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc.","volume":"113","author":"Monsell","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R17-25-20210212","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1044\/jshd.1703.321","article-title":"Development of materials for speech audiometry.","volume":"17","author":"Hirsch","year":"1952","journal-title":"J Speech Hear Disord"},{"key":"R18-25-20210212","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1044\/jshr.2103.507","article-title":"Speech-discrimination scores modeled as a binomial variable.","volume":"21","author":"Thornton","year":"1978","journal-title":"J Speech Hear Res"},{"key":"R19-25-20210212","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","article-title":"Using audiometric thresholds and word recognition in a treatment study.","volume":"27","author":"Halpin","year":"2006","journal-title":"Otol Neurotol"},{"key":"R20-25-20210212","first-page":"179","article-title":"American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc.","volume":"113","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R21-25-20210212","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","article-title":"Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.","volume":"93","author":"Plotkin","year":"2009","journal-title":"J Neurooncol"},{"key":"R23-25-20210212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"key":"R24-25-20210212","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","article-title":"Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.","volume":"21","author":"Mautner","year":"2010","journal-title":"Ann Oncol"},{"key":"R25-25-20210212","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/MAO.0b013e3181b2364c","article-title":"Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.","volume":"30","author":"Fisher","year":"2009","journal-title":"Otol Neurotol"},{"key":"R26-25-20210212","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.","volume":"27","author":"Gray","year":"2009","journal-title":"J Clin Oncol"},{"key":"R27-25-20210212","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","article-title":"RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"R28-25-20210212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.","volume":"29","author":"Allegra","year":"2011","journal-title":"J Clin Oncol"},{"key":"R29-25-20210212","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"key":"R30-25-20210212","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R31-25-20210212","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","article-title":"Rapid vascular regrowth in tumors after reversal of VEGF inhibition.","volume":"116","author":"Mancuso","year":"2006","journal-title":"J Clin Invest"},{"key":"R32-25-20210212","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"R33-25-20210212","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2010.30.2794","article-title":"Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.","volume":"29","author":"Miles","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Otology & Neurotology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MAO.0b013e31825e73f5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:04:31Z","timestamp":1620957871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00129492-201208000-00025"}},"subtitle":["A Retrospective Review of 31 Patients"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mao.0b013e31825e73f5","relation":{},"ISSN":["1531-7129"],"issn-type":[{"value":"1531-7129","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}